Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 7;22(45):9944-9953.
doi: 10.3748/wjg.v22.i45.9944.

Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology

Stefano Crippa  1 , Stefano Partelli  1 , Giulio Belfiori  1 , Marco Palucci  1 , Francesca Muffatti  1 , Olga Adamenko  1 , Luca Cardinali  1 , Claudio Doglioni  1 , Giuseppe Zamboni  1 , Massimo Falconi  1
Affiliations
Review

Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology

Stefano Crippa et al. World J Gastroenterol. .

Abstract

Neuroendocrine carcinomas (NEC) of the pancreas are defined by a mitotic count > 20 mitoses/10 high power fields and/or Ki67 index > 20%, and included all the tumors previously classified as poorly differentiated endocrine carcinomas. These latter are aggressive malignancies with a high propensity for distant metastases and poor prognosis, and they can be further divided into small- and large-cell subtypes. However in the NEC category are included also neuroendocrine tumors with a well differentiated morphology but ki67 index > 20%. This category is associated with better prognosis and does not significantly respond to cisplatin-based chemotherapy, which represents the gold standard therapeutic approach for poorly differentiated NEC. In this review, the differences between well differentiated and poorly differentiated NEC are discussed considering both pathology, imaging features, treatment and prognostic implications. Diagnostic and therapeutic flowcharts are proposed. The need for a revision of current classification system is stressed being well differentiated NEC a more indolent disease compared to poorly differentiated tumors.

Keywords: Chemotherapy; Metastases; Morphology; Neuroendocrine carcinomas; Pancreatic neuroendocrine tumors; Prognosis; Proliferation; Surgery.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: No potential conflicts of interest, no financial support.

Figures

Figure 1
Figure 1
Pancreatic poorly differentiated neuroendocrine carcinomas of the pancreatic body-tail associated with neoplastic thrombosis of the splenic vein/portal vein, and with a lymphadenopathy along the stomach. The patients underwent left pancreatectomy with splenectomy, portal vein resection with portal vein thrombectomy and partial gastric resection.
Figure 2
Figure 2
A small cell poorly differentiated neuroendocrine carcinoma of the pancreas (A) (haematoxylin-eosin stain) and a small cell poorly differentiated neuroendocrine carcinoma of the pancreas with high ki67 proliferative index (B, Ki67: 90%).
Figure 3
Figure 3
Shows a large cell poorly differentiated neuroendocrine carcinoma of the pancreas (A, haematoxylin-eosin stain) and a large cell poorly differentiated neuroendocrine carcinoma of the pancreas with its Ki67 proliferative index (B, Ki67: 80%).
Figure 4
Figure 4
Morphological well differentiated neuroendocrine carcinoma of the pancreas (A, haematoxylin-eosin stain) and morphological well differentiated neuroendocrine carcinoma of the pancreas with Ki67 proliferative index of 30% (B).
Figure 5
Figure 5
Diagnostic flowchart algorithm in patients with pancreatic neuroendocrine carcinomas.
Figure 6
Figure 6
Different therapeutic options in patients with morphological poorly differentiated neuroendocrine carcinomas of the pancreas. 18FDG-PET: 18F-fluorodeoxyglucose positron emission tomography.
Figure 7
Figure 7
Management flowchart algorithm in patients with morphological well differentiated neuroendocrine carcinomas of the pancreas. PRRT: Peptide receptor radionuclide therapy; TAE: Transarterial embolization; TACE: Transarterial chemoembolization; SSA: Somatostatin analogues.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Solcia E, Capella C, Kloppel G, Heitz PU, Sobin LH, Rosai J. Endocrine tumours of the gastrointestinal tract. In: Solcia E, Kloppel G and Sobin LH, editors. Histologic typing of endocrine tumours, WHO international histological classification of tumours. New York: Springer Verlag; 2000. pp. 57–67.
    1. Rindi G, Arnold R, Bosman FT. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In Bosman FT, Carneiro F, Hruban RH and Theise ND. WHO Classification of Tumors of the Digestive System. Lyon: IARC Press; 2010. pp. 13–14.
    1. Crippa S, Partelli S, Boninsegna L, Falconi M. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. Ann Oncol. 2012;23:1928. - PubMed
    1. Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016;103:186–194. - PubMed
    1. Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120:2814–2823. - PubMed

MeSH terms